Notable U.K. government and healthcare leaders, Gamma Knife® radiosurgery experts and representatives of the National Hospital for Neurology and Neurosurgery (NHNN) were amongst those gathered on April 23 to observe the official opening of The Gamma Knife Centre at Queen Square Radiosurgery Centre (QSRC) by the Rt Hon John Bercow, Speaker of the House of Commons. The new centre – which treated its first patients in October 2012 is the United Kingdom’s sixth operational Gamma Knife centre.

Further information about the opening can be found here. Images of the opening can be found on our facebook page.

The Gamma Knife Centre provides a high quality radiosurgical service for National Health Service (NHS) and private patients, and is a partnership between the NHNN, part of the University College London Hospitals (UCLH) NHS Foundation Trust and Medical Equipment Solutions Limited.

The opening program featured several presentations by leading radiosurgery experts who were welcomed by Sir Robert Naylor, Chief Executive, UCLH and included:-

  • Mr. Neil Kitchen, NHNN neurosurgeon; Dr. Naomi Fersht, Consultant Clinical Oncology at University College Hospital and the National Hospital for Neurology and Neurosurgery; Dr. Hans Rolf Jäger, Reader in Neuroradiology at UCL Institute of Neurology and Honorary Consultant Neuroradiologist at UCLH Trust; Ian Paddick, Chief Physicist, NHNN Gamma Knife Centre: Queen Square Gamma Knife Research Beginnings
  • Dr. Dan Leksell, Senior Advisor to Elekta AB: From Inception to Perfexion
  • Mr. Andras Kemeny, Director of the National Centre for Stereotactic Radiosurgery: The Clinical Role of Gamma Knife Radiosurgery in the U.K.
  • Dr. Douglas Kondziolka, Vice chair of Clinical Research and Director of Advanced Radiosurgery, Department of Neurosurgery, NYU Langone Medical Center: How Novel Research Ideas in Gamma Knife Radiosurgery Changed both Neurosurgery and Radiation Oncology

The development of the Gamma Knife Centre supports the U.K. government’s efforts to improve access to advanced clinical techniques and will boost research and clinical efforts on brain disorders.

“In terms of research, the addition of Gamma Knife will enable assessment and evaluation of a range of treatment modalities for brain disorders, particularly for brain metastases,” Mr. Kitchen says. “Clinically, Gamma Knife is a well accepted and proven technology that is a gentle and effective option to standard treatments for brain metastases and other brain disorders that can prolong and improve patients’ quality of life.

A comprehensive and novel research program supported by Elekta is planned, building on the strong platform which already exists at NHNN being part of the University College London Hospitals Foundation Trust, and closely associated in its work with the UCL Institute of Neurology, Queen Square, a major international centre for research and training, with UCL ranked fourth best university in the world.

For further information, please contact:

Pauline Richardson

Director of Operations

[email protected]

About NHNN

Established in 1860, NHNN is the United Kingdom’s largest dedicated neurological and neurosurgical hospital, treating over 6,000 inpatients, 120,000 outpatients and 8,000 day cases each year. NHNN provides comprehensive services for diagnosis, treatment and care of all conditions that affect the brain, spinal cord, peripheral nervous system and muscles. It offers approximately 200 outpatient clinics each week, covering all aspects of neurology, neurosurgery, neuropsychology and neuro-rehabilitation, in addition to many specialist units, including dementia, epilepsy, multiple sclerosis and stroke.

About MESL

A UK based premier provider of niche high technology equipment based healthcare services the team have delivered in excess of £2bn of healthcare projects. Working in partnership MESL provide innovative solutions ensuring clinicians have access to the latest technology, deliver significant value for money and improved patient focused services. MESL is delivering a network of specialist centres in partnership with the NHS across the UK.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: